Ostarine (MK-2866 / Enobosarm) vs YK-11

Mechanism

Ostarine (enobosarm/GTx-024) is a nonsteroidal selective androgen receptor modulator that binds the androgen receptor with high affinity, inducing a conformational change that recruits coactivator proteins preferentially in muscle and bone tissue over prostate and seminal vesicles. This tissue selectivity arises from differential AR cofactor recruitment and 5-alpha reductase metabolism. Ostarine promotes lean body mass by activating AR-mediated transcription of anabolic genes (MYC, IGF-1) in myocytes while minimizing androgenic effects in reproductive tissues. It has demonstrated dose-dependent increases in lean mass in Phase 2 trials.

Standard Dosing

Research indicates 10-25 mg daily orally for 8-12 weeks. Phase 2 clinical trials used 1-3 mg/day with significant lean mass gains.

Timing

Once daily, morning or evening. Consistent timing. Half-life approximately 24 hours. No food timing requirements.

Cycle Duration

8-12 week cycles. PCT may be required depending on suppression level and cycle length.

Side Effects

• Testosterone suppression (dose and duration dependent — mild to moderate)
• Elevated liver enzymes (hepatotoxicity reports)
• HDL suppression
• Headache
• Nausea
• Back pain
• Joint dryness (from estradiol reduction secondary to testosterone suppression)

Contraindications

• Androgen-sensitive cancers (prostate, breast)
• Pre-existing liver disease
• Pregnancy and breastfeeding
• Individuals under 21 (potential endocrine development disruption)
• Athletes subject to WADA testing (prohibited substance)

Best Stacking Partners

Mechanism

YK-11 is a synthetic steroidal compound classified as a gene-selective partial agonist of the androgen receptor. Uniquely among SARMs, YK-11 does not induce the N/C terminal interaction of the AR required for full transcriptional activation, instead selectively activating a subset of AR-dependent genes. Its primary distinguishing mechanism is potent induction of follistatin expression, which directly antagonizes myostatin — a key negative regulator of skeletal muscle mass. This dual action (partial AR agonism + myostatin inhibition via follistatin) theoretically provides anabolic stimulus beyond what full AR agonists alone can achieve.

Standard Dosing

Research indicates 5-15 mg daily orally for 6-8 weeks. No human clinical trials exist — all dosing data is anecdotal.

Timing

Split into 2 daily doses (morning and evening) due to presumed short half-life (~6-10 hours based on structural analysis). Consistent timing essential.

Cycle Duration

6-8 week cycles maximum. PCT strongly recommended. Avoid extended use due to unknown long-term safety profile.

Side Effects

• Testosterone suppression (expected — steroidal compound)
• Hepatotoxicity (17-alpha-alkylated structure implies liver toxicity risk)
• Joint pain and tendon issues (anecdotal — possibly from DHT-like drying effects)
• Hair loss (steroidal androgenic effects)
• Aggression
• Unknown long-term effects (no human studies)

Contraindications

• Pre-existing liver disease
• Androgen-sensitive cancers
• Cardiovascular disease
• Pregnancy and breastfeeding
• Individuals under 21
• Anyone unwilling to accept research chemical risk with zero human clinical data

Best Stacking Partners